摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1265192-83-3

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1265192-83-3
化学式
C15H15Cl2NO3
mdl
——
分子量
328.195
InChiKey
HFMQIAGFUDPKMG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    435.0±55.0 °C(Predicted)
  • 密度:
    1.266±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.95
  • 重原子数:
    21.0
  • 可旋转键数:
    4.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    52.33
  • 氢给体数:
    0.0
  • 氢受体数:
    4.0

反应信息

  • 作为反应物:
    描述:
    在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 以96%的产率得到[2-(2,4-Dichlorophenyl)-5-propan-2-yl-1,3-oxazol-4-yl]methanol
    参考文献:
    名称:
    Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation
    摘要:
    We successfully synthesized a novel peroxisome proliferator-activated receptor (PPAR)delta selective agonist, namely, compound 20, with a characteristic benzisoxazole ring. Compound 20 exhibited potent human PPAR delta transactivation activity and high d selectivity. Further, it stimulated differentiation of primary oligodendrocyte precursor cells in vitro, indicating that it may be an effective drug in the treatment of demyelinating disorders such as multiple sclerosis. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.11.030
  • 作为产物:
    描述:
    三氯氧磷 作用下, 以 为溶剂, 生成
    参考文献:
    名称:
    Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation
    摘要:
    We successfully synthesized a novel peroxisome proliferator-activated receptor (PPAR)delta selective agonist, namely, compound 20, with a characteristic benzisoxazole ring. Compound 20 exhibited potent human PPAR delta transactivation activity and high d selectivity. Further, it stimulated differentiation of primary oligodendrocyte precursor cells in vitro, indicating that it may be an effective drug in the treatment of demyelinating disorders such as multiple sclerosis. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.11.030
点击查看最新优质反应信息